Should you buy Mesa Laboratories (MLAB)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
MLAB currently trades below the base anchor, in the lower half of the engine methodology range.
Engine methodology range — mechanically derived from pipeline gate outputs + peer-multiple inputs. Not an analyst price target. JSON-LD emission gated pending counsel review.
What the engine is tracking
- Product Line Concentration↑Improving
- Weak Revenue Growth→Stable
- Strong Cash Conversion→Stable
- +2 more pillars — see the Why tab for full reasoning
→ Full pillar scorecard with all 5 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Strong Cash Conversion
Trip ifFree cash flow to net income falls below 100% from the current 1000%.
- P2Volatile Earnings Record
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.
- P3Product Line Concentration
Trip ifClinical Genomics share of revenue falls below 60% from the current 80%.
- P4Price Above Analyst Target
Trip ifUpside to the analyst target rises above 10% from the current -17.4%.
- P5Weak Revenue Growth
Trip ifQuarterly revenue rises above $65M for 2 consecutive quarters.
How the engine reached this verdict
TrendMatrix's engine output for Mesa Laboratories, Inc. (MLAB) is HOLD_IF_HOLDING with medium conviction, score 5.3/10 at $131.32. The F-path SELL output reflects an overall score of 4.0 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of -2.76 is supplementary context, not the trigger.
On the bull side: Strong earnings beat streak (3/4); Earnings estimates trending UP; Positive momentum. On the bear side: Concentration risk — Product: Clinical Genomics consumables (80.0%); Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3). Active engine warnings: V8: Target reached (-19.1% upside), L3:NEWS_MOD=+1: SELL_IF_HOLDING → HOLD_IF_HOLDING, V9 Gate Failed: ASYMMETRY:-2.8=NEGATIVE.
The engine is not issuing fresh-money entry targets at the current verdict. The technical entry zone is around — with a technical stop near $122.88 for existing positions. Asymmetric R:R is -2.76, below the threshold (≥2.0) at which the engine would actively flag fresh capital. The engine's sizing output: AVOID at this asymmetry level (no fresh-capital deployment).
HOLD flips toward BUY_WAIT if reward-to-risk (NEGATIVE) clears AND a co-confirming gate triggers. HOLD flips toward SELL if any of the currently-passing gates drop below threshold OR three or more dimensions fall below 4 simultaneously.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates MLAB — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (3/4)
- ▸Earnings estimates trending UP
- ▸Positive momentum
Bear case
- ▸Concentration risk — Product: Clinical Genomics consumables (80.0%)
- ▸Analyst target reached - limited upside remaining
- ▸V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3)